{
    "Clinical Trial ID": "NCT02807844",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W",
        "  Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W",
        "INTERVENTION 2: ",
        "  Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W",
        "  Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W"
    ],
    "Eligibility": [
        "Main Inclusion Criteria:",
        "  Signed informed consent prior to any procedures",
        "  Phase Ib part: Adult patients with advanced melanoma, endometrial carcinoma, pancreatic or TNBC, with measurable or non-measurable disease who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists.",
        "  Phase II part: Adult patients with advanced solid tumors who have received standard therapy (no more than 3 prior lines of treatment) or are intolerant of standard therapy, have progressed following their last prior therapy, and fit into one of the following groups:",
        "  Group 1: TNBC who did not receive prior anti-PD-1/PD-L1 treatment",
        "  Group 2: Pancreatic adenocarcinoma who did not receive prior anti-PD-1/PD-L1 treatment",
        "  Group 3: Endometrial carcinoma who did not receive prior anti-PD-1/PD-L1 treatment",
        "  Group 4: Melanoma who progressed on prior anti-PD-1/PD-L1 treatment.",
        "  Main Exclusion Criteria:",
        "  Patients with the following:",
        "  Symptomatic central nervous system (CNS) metastases or those requiring local CNS-directed therapy.",
        "  Abnormal liver, renal, or blood lab values.",
        "  Impaired cardiac function or clinically significant cardiac disease.",
        "  Active autoimmune disease or documented autoimmune disease within 3 years of screening.",
        "  Active infection requiring antibiotic therapy.",
        "  Known HIV, active hepatitis B or C virus.",
        "  Concurrent malignant disease.",
        "  Patients who received systemic anticancer therapy, major surgery, or radiotherapy within 2 weeks of study treatment, or live vaccines within 4 weeks of study treatment.",
        "  Patients requiring chronic treatment with systemic steroid therapy or any immunosuppressive therapy.",
        "  Patients who used hematopoietic colony-stimulating growth factors within 2 weeks of study treatment."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Phase Ib: Percentage of Participants With Adverse Events, as a Measure of Safety",
        "  Phase Ib: To characterize the safety and tolerability of MCS110 in combination with PDR001 in patients with advanced solid malignancies and to identify a recommended dose combination for Phase II.",
        "  Time frame: From start of treatment to a maximum timeframe of 116.4 weeks for phase Ib",
        "Results 1: ",
        "  Arm/Group Title: Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W",
        "  Arm/Group Description: Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W",
        "  Overall Number of Participants Analyzed: 6",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  Adverse events (AEs) - all grades: 6 100.0%",
        "  Adverse events - Treatment-related - all grades: 6 100.0%",
        "  Serious Adverse Events (SAEs) - all grades: 3  50.0%",
        "  SAEs - Treatment-related - all grades: 0   0.0%",
        "  Fatal SAEs - all grades: 0   0.0%",
        "  Fatal SAEs - Treatment-related - all grades: 0   0.0%",
        "  AEs leading to discontinuation - all grades: 0   0.0%",
        "  AEs leading to discontinuation - Treatment-related - all grades: 0   0.0%",
        "  AEs leading to dose adjustment / interruption - all grades: 4  66.7%",
        "  AEs requiring additional therapy - all grades: 6 100.0%",
        "Results 2: ",
        "  Arm/Group Title: Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W",
        "  Arm/Group Description: Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W",
        "  Overall Number of Participants Analyzed: 12",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  Adverse events (AEs) - all grades: 12 100.0%",
        "  Adverse events - Treatment-related - all grades: 12 100.0%",
        "  Serious Adverse Events (SAEs) - all grades: 4  33.3%",
        "  SAEs - Treatment-related - all grades: 1   8.3%",
        "  Fatal SAEs - all grades: 0   0.0%",
        "  Fatal SAEs - Treatment-related - all grades: 0   0.0%",
        "  AEs leading to discontinuation - all grades: 0   0.0%",
        "  AEs leading to discontinuation - Treatment-related - all grades: 0   0.0%",
        "  AEs leading to dose adjustment / interruption - all grades: 4  33.3%",
        "  AEs requiring additional therapy - all grades: 12 100.0%"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 3/6 (50.00%)",
        "  Anaemia 0/6 (0.00%)",
        "  Abdominal pain 1/6 (16.67%)",
        "  Ascites 0/6 (0.00%)",
        "  Constipation 0/6 (0.00%)",
        "  Dyspepsia 1/6 (16.67%)",
        "  Gastric haemorrhage 0/6 (0.00%)",
        "  Gastrointestinal haemorrhage 0/6 (0.00%)",
        "  Haemoperitoneum 0/6 (0.00%)",
        "  Intestinal obstruction 0/6 (0.00%)",
        "  Intestinal perforation 1/6 (16.67%)",
        "  Large intestinal obstruction 1/6 (16.67%)",
        "Adverse Events 2:",
        "  Total: 4/12 (33.33%)",
        "  Anaemia 0/12 (0.00%)",
        "  Abdominal pain 0/12 (0.00%)",
        "  Ascites 0/12 (0.00%)",
        "  Constipation 0/12 (0.00%)",
        "  Dyspepsia 0/12 (0.00%)",
        "  Gastric haemorrhage 0/12 (0.00%)",
        "  Gastrointestinal haemorrhage 0/12 (0.00%)",
        "  Haemoperitoneum 0/12 (0.00%)",
        "  Intestinal obstruction 0/12 (0.00%)",
        "  Intestinal perforation 0/12 (0.00%)",
        "  Large intestinal obstruction 0/12 (0.00%)"
    ]
}